Blood Cancer Drug Discoveries
What the Future Holds
| Product Code | ESP00481 |
| Publication Date | April 2008 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 245 |
| ISBN Number | 978-1-85822-314-8 |
Blood Cancer Drug Discoveries
What the Future Holds
This New Strategic Report from Espicom Provides A Comprehensive Review of Current and Future Treatments for Major Blood Cancer Therapy Areas: Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Acute Myeloid Leukaemia, Multiple Myeloma and Non-Hodgkin's Lymphoma.
Over 275 Pages of Product Analysis, Market Statistics and Forecasts Unique Market Share and 5-Year Sales Forecasts for Leading Products & Pipeline Prospects A Comprehensive Examination of Major Blood Cancer Therapy Areas Critical Competitive Evaluation and Scoring of Current and Future Products.
Providing...
- Detailed Analysis and 5-Year Forecasts for Current Leading Products by Value
- A Detailed Review and Assessment of up and Coming Products
- Unique Product Assessment and Scoring
- An Evaluation of The Current Understanding of Blood Cancers
Major Areas Covered
- Chronic Lymphocytic Leukaemia
- Chronic Myeloid Leukaemia
- Acute Myeloid Leukaemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
The Report Covers Major Blood Cancer Areas
- Chronic Lymphocytic Leukaemia
- Chronic Myeloid Leukaemia
- Acute Myeloid Leukaemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
The Market
- Risk Factors, How The Disease Affects Patients, Diagnosis and Stages of The Disease
- The Market in 2007 and 2012
- Growth Drivers and Dampeners
Patient Statistics
- Prevalence
- Diagnosis Rates
- Unmet Clinical Need
Current Treatment Options
- Interventions by Type
- Unique Five Point Competitive Assessment and Scoring of Current Therapies and Companies Involved
- 5-Year Sales Forecasts for Key Products
R&d: Drugs in Late Stage Development
- Focus on New Classes of Drugs and The Companies Involved
- Unique Competitive Assessment and Scoring of New Therapies and Companies Involved
- 5-Year Sales Forecasts for Key Products from Year of Launch
Extensive Tables and Charts
Contents
- Blood Cancers
- US Incidence of Blood Cancers, 2007
- Unmet Medical Need
- New Agents in Development
- New Mechanisms of Action under Investigation for The Development of Blood Cancers:
- Monoclonal Antibodies in Development for Treatment of Blood Cancers
- Major Players
- 2007
- Market Share of Players in The Worldwide Blood Cancers Market, 2007
- 2012
- Market Share of Players in The Worldwide Blood Cancers Market, 2012
- Global Sales
- Estimated and Forecast Worldwide Sales in The Treatment of Blood Cancers (US$ Millions)
- Regional Breakdown of Blood Cancer Market by Sales - 2007 and 2012
- Chronic Lymphocytic Leukaemia
- Background
- Patient Statistics
- Patient Model
- Estimated Prevalence of Cll in Major Markets, 2005-2012
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global Market
- Forecast Cll Market Growth (US$ Millions)
- Major Players
- Current Drugs Commonly Used in The Treatment of Cll
- Major Players in Cll by Sales - 2007
- Forecast Major Players in Cll by Sales - 2012
- The Drugs
- Current Drugs
- Selected Response Rates from Studies of First Line Treatment of Cll:
- Fludara
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Fludara Sales in Cll by Region (US$ Millions)
- Forecast Fludara Sales in Cll by Use (US$ Millions)
- Competitor Ratio Analysis
- Rituxan
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Blood Cancer Drug Discoveries: What The Future Holds
- Sales Forecasts and Assumptions
- Forecast Rituxan Sales in Cll by Use (US$ Millions)
- Forecast Rituxan Sales in Cll by Region (US$ Millions)
- Competitor Ratio Analysis
- Campath
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Campath Sales in Cll by Use (US$ Millions)
- Competitor Ratio Analysis
- Agents in Development
- Drugs in Development for The Treatment of Cll
- Agents in Late Stage Development for Cll:
- Treanda
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Treanda Sales in Cll (US$ Millions)
- Competitor Ratio Analysis
- Genasense
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Genasense in Cll Efficacy Summary:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Genasense Sales in Cll by Region (US$ Millions):
- Forecast Genasense Sales in Cll by Use (US$ Millions):
- Competitor Ratio Analysis
- Ofatumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Ofatumumab Sales in Cll by Region (US$Millions):
- Forecast Ofatumumab Sales in Cll by Use (US$Millions):
- Competitor Ratio Analysis
- Alvocidib
- Blood Cancer Drug Discoveries: What The Future Holds
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Alvocidib Sales in Cll (US$ Millions)
- Competitor Ratio Analysis
- Lumliximab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Lumiliximab Sales in Cll (US$ Millions)
- Competitor Ratio Analysis
- Revlimid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Revlimid Cll Sales by Use (US$ Millions):
- Forecast Revlimid Cll Sales by Region (US$ Millions):
- Competitor Ratio Analysis
- Chronic Myeloid Leukaemia
- Background
- Patient Statistics
- Trends in US Cml Incidence:
- Estimated Incidence in Worldwide Cml Prevalence:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global Market
- Forecast Worldwide Cml Market (US$ Millions)
- Major Players - 2007
- Major Players in Cml by Sales - 2007
- Major Players - 2012
- Forecast Major Players in Cll by Sales - 2012
- The Drugs
- Cml Treatment Timeline:
- Current Drugs
- Current Drugs Used in The Treatment of Cml:
- Gleevec/Glivec
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Blood Cancer Drug Discoveries: What The Future Holds
- Iris Study: 18-Month Response Rates Determined by Intent-to-Treat Analysis
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Gleevec Sales in Cml (US$ Millions) - Excludes Sales in Gist
- Competitor Ratio Analysis
- Sprycel
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Sprycel Cml Sales (US$ Millions):
- Competitor Ratio Analysis
- Tasigna
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Tasigna Cml Sales Forecast (US$ Millions)
- Competitor Ratio Analysis
- Agents in Development
- Drugs in Development for The Treatment of Cml:
- Agents in Late Stage Development for Cml:
- Bosutinib
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Bosutinib Sales in Cml (US$ Millions)
- Competitor Ratio Analysis
- Panobinostat
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Mk-0457/ Vx 680
- Blood Cancer Drug Discoveries: What The Future Holds
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Acute Myeloid Leukaemia
- Background
- French-American-British (Fab) Classification of Aml
- Who Aml Classification:
- Selected Risk Factors Associated with Aml:
- Common Chromosomal Abnormalities in Aml:
- Patient Statistics
- Forecast Incidence of Aml by Region:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global Market
- Forecast Worldwide Adult Aml Market
- Major Players - 2007
- Major Players - 2012
- Forecast Major Players in Aml by Sales - 2012
- The Drugs
- Treatment Nave Patients
- Relapsed & Refractory Aml
- Current Drugs Used in The Treatment of Aml:
- Therapeutic Strategies in Aml and Relapsed/Refractory Aml:
- Mylotarg
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Summary of Response Rates in Mylotarg Studies:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Agents in Development
- Agents in Late Stage Development for Aml:
- Clolar/Evoltra
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Clolar/Evoltra in Adult Aml (US$ Millions):
- Competitor Ratio Analysis
- Blood Cancer Drug Discoveries: What The Future Holds
- Cloretazine
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Cloretazine in Aml (US$ Millions)
- Competitor Ratio Analysis
- Zarnestra
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Dacogen
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Dacogen Sales in Adult Aml (US$ Millions)
- Competitor Ratio Analysis
- Lestaurtinib
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Lestaurtinib Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
- Midostaurin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Midostaurin Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
- Tandutinib
- Novelty/Rationale for Mechanism of Action
- Blood Cancer Drug Discoveries: What The Future Holds
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Zosuquidar
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Xanafide
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Xanafide Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
- Ceplene
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Ceplene Sales in Aml (US$ Millions)
- Competitor Ratio Analysis
- Multiple Myeloma
- Background
- Patient Statistics
- Patient Model
- Estimated Prevalence of Multiple Myeloma in Selected Markets
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global Market
- Forecast Worldwide Multiple Myeloma Market (US$ Millions):
- Major Players
- Major Players in Multiple Myeloma by Sales - 2007
- Major Players in Multiple Myeloma by Sales - 2012
- Current Drugs Used in The Treatment of Multiple Myeloma:
- The Drugs
- Blood Cancer Drug Discoveries: What The Future Holds
- Thalomid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Thalomid Sales in Multiple Myeloma (US$ Millions)
- Competitor Ratio Analysis
- Revlimid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Data Summary of Mm-009 and Mm - 010 Studies:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Front Line Myeloma Comparison:
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Velcade
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Velcade Sales in Multiple Myeloma (US$ Millions)
- Competitor Ratio Analysis
- Agents in Development
- Drugs in Development for The Treatment of Multiple Myeloma:
- Agents in Late Stage Development for Multiple Myeloma:
- Tanespimycin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Tanespimycin Sales in Relapsed/Refractory Multiple Myeloma (US$ Millions)
- Competitor Ratio Analysis
- Mapatumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Blood Cancer Drug Discoveries: What The Future Holds
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Belinostat
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Perifosine
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Carfilzomib
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Non Hodgkin's Lymphoma
- Background
- Frequency of Nhl Subtypes in Adults:
- 1) B-Cell Cll/Small Lymphocytic Lymphoma
- 2) Marginal Zone Lymphoma
- 3) Lymphoplasmocytic Lymphoma (Waldenstrom Macroglobulinemia):
- 4) Follicular Lymphoma:
- 1) Cutaneous T-Cell Lymphoma:
- 1) Diffuse Large B-Cell Lymphoma (Dlbcl):
- 2) Mantle Cell Lymphoma:
- 3) Burkitt Lymphoma/Burkitt-like Lymphoma:
- 4) Precursor B-Cell Leukaemia/Lymphoma
- 1) Anaplastic Large T/Null-Cell Lymphoma:
- 2) Precursor T-Lymphoblastic Lymphoma/Leukaemia:
- 3) Peripheral T-Cell Lymphomas:
- Staging Systems
- Patient Statistics
- Patient Model
- Forecast Nhl Incidence and Prevalence (000s)
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Blood Cancer Drug Discoveries: What The Future Holds
- Global Market
- Forecast Nhl Market (Excluding Ctcl) - US$ Millions
- Forecast Ctcl Market - US$ Millions
- Major Players
- Current Drugs Commonly Used in The Treatment of Nhl
- Major Players in Nhl by Sales - 2007
- Major Players in Nhl by Sales - 2012
- The Drugs
- Low Grade or Indolent Nhl
- Treatment Options in Indolent/Low-Grade Nhl:
- Intermediate- and High-Grade Lymphomas:
- T-Cell Lymphomas:
- Summary of Common Therapies in Nhl
- Marketed Agents for Use in Nhl
- Rituxan
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Rituxan Penetration Rates, Q3-Q4 2005
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Rituxan Sales in Nhl Indications by Region (US$ Millions)
- Forecast Rituxan Sales in Nhl Indications by Use (US$ Millions)
- Competitor Ratio Analysis
- Fludara
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Fludara Sales in Nhl Indications (US$ Millions)
- Competitor Ratio Analysis
- Bexxar
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Bexxar Sales (US$ Millions):
- Competitor Ratio Analysis
- Zevalin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Blood Cancer Drug Discoveries: What The Future Holds
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Zevalin Sales (US$ Millions)
- Competitor Ratio Analysis
- Marketed Agents for Cutatenous T-Cell Lymphoma
- Zolinza
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Zolinza Sales in Ctcl (US$ Millions)
- Competitor Ratio Analysis
- Agents in Development
- Drugs in Development for The Treatment of Nhl:
- Agents in Late Stage Development for Nhl:
- Treanda
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Treanda US Sales Forecasts in Nhl Indication (US$ Millions)
- Competitor Ratio Analysis
- Ofatumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Phase I/Ii Trial Results Summary:
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Ofatumumab in Nhl by Region (US$ Millions):
- Forecast Sales of Ofatumumab in Nhl by Use (US$ Millions):
- Competitor Ratio Analysis
- Galiximab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Galiximab Sales in Nhl (US$ Millions)
- Competitor Ratio Analysis
- Blood Cancer Drug Discoveries: What The Future Holds
- Pixantrone
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Pixantrone Nhl Sales by Region (US$ Millions):
- Forecast Pixantrone Sales in Nhl by Use (US$ Millions)
- Competitor Ratio Analysis
- Revlimid
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Revlimid Sales Forecasts in Nhl (US$ Millions)
- Competitor Ratio Analysis
- Torisel
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Torisel Sales in Mcl (US$ Millions)
- Competitor Ratio Analysis
- Velcade
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Velcade Sales in Mcl (US$ Millions)
- Forecast Velcade Sales in Follicular Nhl (Excludes Mcl) by Region (US$ Millions)
- Forecast Velcade Sales in Follicular Nhl (Excludes Mcl) by Use (US$ Millions)
- Competitor Ratio Analysis
- Inotuzumab Ozogamicin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Blood Cancer Drug Discoveries: What The Future Holds
- Competitor Ratio Analysis
- Agents in Late Stage Development for Cutaneous T-Cell Lymphoma
- Zanliumumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Zanolimumab in Ctcl (US$ Millions)
- Competitor Ratio Analysis
- Belinostat
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Belinostat in Ctcl (US$ Millions)
- Competitor Ratio Analysis
- Fodosine
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Forecast Sales of Fodosine in Ctcl (US$ Millions)
- Competitor Ratio Analysis
- Epratuzumab
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Enzastaurin
- Novelty/Rationale for Mechanism of Action
- Proof of Concept/Clinical Data
- Management/Clinical Expertise
- Competition within The Marketplace/Gaining Share of Voice
- Risks Associated with Developing A Drug within A Therapeutic Class
- Filings and Approval
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Cra Analysis: Aml
- Blood Cancer Drug Discoveries: What The Future Holds
- Cra Summary
- Cra Analysis: Cml
- Cra Summary
- Cra Analysis: Cll
- Cra Analysis: Multiple Myeloma
- Cra Summary
- Cra Analysis: Nhl
- Cra Analysis - Nhl
- Cra Analysis - Nhl (Continued)...includes Ctcl
- Acronyms